Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on September 22.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Kairos Pharma’s promising developments. The company’s lead candidate, ENV-105, is showing encouraging results in ongoing clinical trials, particularly in metastatic castration-resistant prostate cancer (mCRPC). Interim data from their Phase 2 study indicates a median progression-free survival (PFS) of over 13 months, which exceeds current benchmarks and suggests potential for significant therapeutic impact.
Additionally, ENV-105 targets CD105, a protein involved in tumor angiogenesis, which is a key driver of cancer resistance. By blocking CD105, ENV-105 may re-sensitize tumors to standard-of-care therapies, offering a novel approach to overcoming drug resistance. The upcoming presentation at the European Society for Medical Oncology (ESMO) Congress is expected to further highlight these promising findings, supporting the positive outlook for Kairos Pharma’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Atossa Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -14.1% and a 37.22% success rate on recommended stocks.
In another report released on September 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.